Regeneron Pharmaceuticals REGN announced that the FDA has approved extending dosing intervals of up to every 20 weeks for ...

The stock is one of only two in IBD's biotech group with highest-possible 99 Composite Ratings.

Regeneron (REGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Regeneron Pharmaceuticals (REGN) is back in focus after Japan approved Dupixent as the first targeted treatment for adults ...

Piper Sandler starts Regeneron at overweight with $875 price target, citing Dupixent growth and pipeline catalysts. Read more ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Regeneron (REGN +0.93%) has encountered several headwinds over the past two years, including the loss of patent exclusivity ...

Nvidia (NVDA) reported Q4 FY2026 revenue of $68.13B, up 73.2% year-over-year and beating estimates, with Data Center Networking surging 263% year-over-year as NVLink adoption accelerated. Short-term ...

Is REGN a good stock to buy? We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Ocular Capital’s Substack. In this article, we will summarize the bulls’ thesis on REGN. Regeneron ...

Stock prices for Ford Motor Co., General Motors and Jeep-owner Stellantis all fell for the week ending Friday, March 13. Detroit Three stock prices fluctuated during the week and ended on a down note ...

Stocks slid again as oil prices spiked on Friday, as the major indexes fell for a third-straight week. The Dow Jones Industrial Average fell 119 points, or 0.3%. The S&P 500 was down 0.6%. The Nasdaq ...

This is read by an automated voice. Please report any issues or inconsistencies here. The stock market remained calm Wednesday, even as the price of oil got back to rising. The Standard & Poor’s 500 ...